Solid Biosciences’ SGT-501 Gene Therapy for CPVT Earns FDA Fast Track Status

Solid Biosciences Inc., a clinical-stage leader in precision genetic medicines for neuromuscular and cardiac disorders, has secured Fast Track designation from the U.S. Food and Drug Administration (FDA) for its innovative AAV-based gene therapy, SGT-501, designed to treat catecholaminergic polymorphic ventricular tachycardia (CPVT).

SGT-501 aims to deliver a fully functional, codon-optimized version of the human cardiac calsequestrin (CASQ2) gene to heart muscle cells. This approach targets the root cause of CPVT by stabilizing ryanodine receptor (RYR2) activity and correcting calcium dysregulation, which helps restore normal heart rhythm during diastole and may prevent dangerous ventricular tachycardia.

The FDA’s Fast Track designation, reserved for therapies addressing serious or life-threatening conditions with unmet medical needs, will accelerate SGT-501’s development through enhanced FDA collaboration and potential eligibility for priority review. The therapy has also received Orphan Drug and Rare Pediatric Disease designations, underscoring its potential as a groundbreaking treatment for CPVT, a condition with no FDA-approved therapies targeting its underlying mechanisms.

Dr. Jessie Hanrahan, Solid Biosciences’ Chief Regulatory & Preclinical Operations Officer, stated, “The FDA’s IND clearance and Fast Track designation validate SGT-501’s potential to transform treatment for CPVT, a devastating condition with significant unmet needs. Our robust preclinical data and regulatory expertise position SGT-501 as a promising first-in-class therapy. We’re grateful for the FDA’s partnership and eager to advance this program globally.”

On July 8, 2025, SGT-501 received FDA Investigational New Drug (IND) clearance and Health Canada Clinical Trial Application (CTA) approval. A first-in-human Phase 1b trial, set to begin in Q4 2025, will assess the therapy’s safety, tolerability, and efficacy in a multicenter, open-label study.

CPVT, affecting approximately 1 in 10,000 people, is a rare cardiac disorder often misdiagnosed in children and young adults. Triggered by physical or emotional stress, it causes abnormal heart rhythms that can lead to fainting, seizures, cardiac arrest, or sudden death. Mutations in the RYR2 and CASQ2 genes disrupt calcium regulation in heart cells, impairing normal heart function. SGT-501’s approach, pioneered by Dr. Silvia Priori’s team at IRCCS Maugeri Pavia, Italy, and licensed by Solid Biosciences in 2023, enhances CASQ2 protein levels to stabilize RYR2, reducing calcium leaks and supporting normal heart rhythm.

Solid Biosciences continues to advance its portfolio of gene therapies for rare diseases, including Duchenne muscular dystrophy, Friedreich’s ataxia, and other genetic cardiac conditions, aiming to deliver life-changing treatments to patients worldwide.